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Cardiometabolic disorders (CMDs), including ischemic heart disease, stroke and type
2 diabetes are the leading causes of mortality and morbidity in women worldwide. The
burden of CMDs falls disproportionately on low and middle-income countries (LMICs),
placing substantial demands on already pressured health systems. Cardiometabolic
disorders may present up to a decade earlier in some LMIC settings, and are associated
with high-case fatality rates. Early identification and ongoing postpartum follow-up of
women with pregnancy complications such as hypertensive disorders of pregnancy
(HDPs), and gestational diabetes mellitus (GDM) may offer opportunities for prevention,
or help delay onset of CMDs. This mini-review paper presents an overview of the
key challenges faced in the early identification, referral and management of pregnant
women at increased risk of CMDs, in low-resource settings worldwide. Evidence-based
strategies, including novel diagnostics, technology and innovations for early detection,
screening and management for pregnant women at high-risk of CMDs are presented.
The review highlights the key research priorities for addressing cardiometabolic risk in
pregnancy in low-resource settings.
Keywords: high-risk pregnancy, preeclampsia, gestational diabetes, cardiometabolic disorders, cardiovascular
disease
INTRODUCTION
Significant physiological changes occur during pregnancy. These may affect a woman’s
cardiovascular, immune and metabolic functions and unmask susceptibility for developing
cardiometabolic disorders (CMDs) (1, 2). Women with a history of Hypertensive Disorders of
Pregnancy (HDPs, including preeclampsia), Gestational Diabetes Mellitus (GDM), spontaneous
preterm birth, and delivery of a small for gestational age (SGA) baby, display increased risk of future
CMDs: including cardiovascular disease (CVD), stroke, Type 2 Diabetes (T2DM) and chronic
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kidney disease (CKD) (3–7). Pregnancy complications are no
longer seen as isolated conditions affecting pregnancy, but
independent risk factors for future CVD (5, 8).
Women are more likely to die from CVD because of late
presentation and differences in symptomatology (9). The burden
of premature deaths from complications of pregnancy such as
preeclampsia, preterm birth and SGA babies and CVD later
in life, fall disproportionately upon Low-and Middle-Income
Countries (LMICs) (10, 11). Women in rural areas of LMICs
are further disadvantaged due to limitations in healthcare access
and infrastructure, issues of poverty, and educational and socio-
cultural barriers in accessing timely care as well as engaging with
ongoing treatment (12, 13).
This review discusses the research priorities for improving
women’s cardiometabolic health in low-resource settings in
LMICs following a high-risk pregnancy. We focus on three main
areas related to the provision of universal health coverage: (1)
Community-level interventions for high-risk pregnancies; (2)
The need for life-course based approaches to women’s health,
and (3) Improving equity and access to affordable treatments
for CMDs.
Community-Level Interventions for
High-Risk Pregnancies
Preventative efforts to avert CMDs often start too late to be
effective (3). Early detection and management of women with
pregnancy complications associated with a high-risk of future
CMDs requires active community engagement to encourage
early, regular antenatal care (ANC) attendance (14).
In low-resource settings, where multiple clinic visits may
not be feasible, point-of-care tests (POCT) have been used by
Community Health Workers (CHWs), nurses and doctors to
screen for HIV/AIDS, malaria and anemia during pregnancy
(14). Potential biomarkers for first trimester preeclampsia
screening include serum placental growth factor (PlGF), serum
pregnancy-associated plasma protein A (PAPP-A), mean arterial
pressure (MAP) and uterine artery pulsatility index (UTPI)
(15). Point of care tests for these emerging biomarkers merit
further country-specific, clinical, and economic evaluation (16).
The implementation of novel diagnostics in LMICs, must be
coupled with upgrading of laboratory facilities in primary care
settings, which are insufficiently prioritized by governments
worldwide (17).
The detection of HDPs mainly involves blood pressure
(BP) measurement and urinalysis. Whilst non-invasive, these
skills can be intimidating to rural healthcare workers. To
improve community-level detection of HDPs in LMICs, low-
cost instruments have been developed and validated for use
by frontline healthcare workers in low-resource settings. The
CRADLE Vital Signs Alert device is a novel, semi-automated
BP device, validated for use in pregnancy and to stratify risk
in pregnant women with both high and very low BP, costing
∼$20 USD (18). Feasibility studies have shown high levels
of acceptability by Community Health Workers (CHWs) in
Nigeria, Mozambique, Zimbabwe, Ethiopia and India (18, 19).
A large stepped-wedge cluster-randomized controlled trial across
10 LMICs was; however, unable to demonstrate impact on
the primary composite outcomes of maternal mortality and
morbidity (20). This may be due, in part, to insufficient power
and sample size, and significant variations between clusters (20).
Low cost urinalysis devices for proteinuria detection have also
been developed and piloted (21–23), although evidence of impact
on clinical endpoints is lacking.
Community-based screening for GDM is complicated by a
lack of attendance, and lack of consolidated criteria for testing
and diagnosis of GDM (24). Routine application of the gold
standard fasting oral glucose tolerance test (OGTT), followed
by venous blood being drawn at 0, 1, and 2 hours post-glucose
load is not feasible in rural settings where mothers have to
travel long distances and wait substantial amounts of time to
receive antenatal services, and healthcare staff skilled in drawing
blood are not available at specified times (24). Some rural
centers perform OGTTs irrespective of fasting status. A study
from India, testing women irrespective of their fasting state, did
not reveal statistically different results compared to the WHO-
recommended fasting 75-g OGTT (25). Subsequent studies have,
however, found the sensitivity of non-fasting tests to be low (26).
In response to the growing burden of GDM in India, pragmatic
guidelines for low-resource settings have been developed (24, 27);
however, the operability of such guidelines relies heavily on the
presence of good laboratory and primary care infrastructure.
The Role of Mobile Technologies
Mobile health (mHealth) technologies have the potential to
increase equity, quality and efficiency of service delivery
in LMICs (28). mHealth technologies have contributed to
reductions in delays in accessing maternal health in LMICs (29),
and can be useful in the diagnosis, monitoring, providing clinical
decision support, education and health promotion (30, 31).
A large-scale cluster randomized trial of a multi-faceted
smartphone-based mHealth intervention (ImTECHO) used by
CHWs to deliver care to pregnant women in their homes,
involving a population of almost half a million in rural
Gujarat in India, demonstrated improved engagement and
delivery of antenatal and postnatal care by CHWs (32). The
platform facilitated longitudinal tracking, scheduling of health
services, screening for complications, counseling and behavior
change communication, and real-time mentoring and supportive
supervision of CHWs. This study highlighted the feasibility and
effectiveness of mobile phone technologies as job aids to frontline
healthcare workers to strengthen the local health system, but
did not demonstrate a positive impact on maternal or neonatal
mortality (32).
Similar interventions have potential to extend beyond the
immediate postpartum period for long-term follow up of
women at high risk of future CMDs. Future research should
focus on rigorous evaluation of mHealth interventions beyond
pilot studies (33), and include process evaluation and cost-
effectiveness analyses, with a focus on local ownership and
integration within existing health systems.
Risk stratification tools for pregnant women with
preeclampsia have been developed for predicting risk of
adverse maternal outcomes (34, 35). The full-Pre-eclampsia
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Integrated Estimate of RiSk model (fullPIERS) is a prediction
model based on clinical history, signs and symptoms and
laboratory tests. Developed in a High-Income Country (HIC)
context, it has also been validated for use in low-resource settings
(36, 37); however, is reliant on full laboratory-based support
(35). A succinct version, based on symptoms and signs alone
(miniPIERS), has also been developed for community-based risk
assessment (34). These tools provide clinical decision support
to frontline healthcare workers and may be integrated into
mHealth platforms, such as the PIERS-on-the-move (POM)
mHealth platform (38). A study of the POM mHealth platform,
demonstrated good levels of acceptability, feasibility, and
moderate utility for the prediction of adverse maternal outcomes
in women with HDPs (39).
While these tools may be used for identification and
risk-stratification of high-risk women during pregnancy, little
evidence is currently available to calculate or predict long-
term cardiovascular risk in this population (40). Robust data
collection systems are needed for the long-term follow-up of
women in LMICs to study the true prevalence and impact of
high-risk conditions in pregnancy on future CMDs, and enable
accurate risk stratification of high-risk women. It is unclear if
existing cardiovascular risk predictionmodels could be improved
through the addition of history of pregnancy complications
(41, 42). There is a need for prognostic models using sample
populations reflecting the diversity of target populations, and
involving both nulliparous and multiparous women to better
identify women at high-risk of CMD during and after pregnancy
(40).Women who develop T2DM following GDM in some LMIC
settings are more likely to exhibit certain characteristics such as
increased body mass index postpartum, family history of T2DM,
and certain ethnicities (43, 44). It is unclear, however, if these
clinical features may be used to guide risk stratification of women
with GDM and their progression to T2DM across other LMIC
settings, as they are based on small-scale studies. A systematic
review on the progression of GDM to T2DM concluded that a
markedly raised fasting glucose level during pregnancy was most
highly predictive of progression to T2DM, and did not support
the use of features such as ethnicity, BMI, and family history of
T2DM for risk stratification of progression to T2DM in pregnant
women (45).
Task-Sharing in the Community
Task-sharing has potential to empower and engage community
members, improve efficiency, and “expand the reach of delegated
medical acts” (46). In areas with a shortage of doctors and nurses
in LMICs, CHWs have been deployed to deliver interventions for
the early detection of high-risk pregnant women (18, 47–49) and
enable community-based data collection (50). CHWs have high
levels of trust and respect within their communities, andmotivate
women to engage with antenatal care (51). Task-sharing relies
upon continuous training and supervision, as CHWs may have
limited literacy in low-resource settings (14).
The community-based management of hypertension in Nepal
(COBIN) cluster randomized controlled trial in the general
adult population of Nepal, established the effectiveness of
a CHW-led home-based health education and screening for
the reduction of Systolic BP (of almost 5 mmHg), in adults
with hypertension; and amelioration of age-related increases
in BP in adults without hypertension (52). Further examples
of community-based programmes with potential to reduce
cardiovascular risk in LMIC settings exist (53–56), however
as the COBIN trial team concluded; long-term trials with
hard clinical outcomes, such as myocardial infarction and
stroke as primary endpoints are needed to confirm the effect
of CHW-led interventions on cardiovascular mortality and
morbidity (52). Important areas for future research would
be to conduct adequately sized, robustly designed trials,
demonstrating tangible impact upon mortality across the life-
course, including cost effectiveness analyses, and exploration of
the impact of climate change and seasonal variations on BP-
related endpoints (57, 58).
LMIC-Based Data Repositories and
Biobanks
Research associating pregnancy complications with CVD risk
have, to date, been derived from linkage of large national data
sets from high income countries (HIC) (41, 59, 60). Unlike
HICs, the majority of CVD deaths in sub-Saharan Africa are
due to stroke rather than ischemic heart disease (61), which may
reflect differences in etiology. Currently, there are insufficient
data on the life-long health of women living in LMIC settings.
Encouraging collaboration across LMICs to form consortia for
uniform women’s health related data collection such as the
COLLECT database for collaborative pregnancy and placental
research (62), started by the Global Pregnancy Collaboration
(CoLab) (63), might facilitate the use of big data analytics
to enable risk stratification of women with pregnancy-related
risk factors for CMDs in LMICs, and identify key timings
for interventions.
With the fast-developing world of genomics, proteomics and
metabolomics, LMICs might benefit from establishing biobanks.
This would encourage locally-driven -omics research, based on
the needs and priorities of LMICs, with local data ownership.
South-south as well as north-south collaborations have potential
to improve research into biomarkers for risk factors for CMD
in women, including pregnancy-related risk factors such as
preterm birth, pre-eclampsia, and GDM. The significant genetic
variations in South Asian and African populations are important
to furthering our knowledge of disease etiology and drug
development. Currently, the majority of DNA used for research
studies come from participants of European descent, with only
2% of data contributed from African data sets (64). In response, a
new pan-Africa biobank start-up, 54-gene (64) and additionally,
the first pan-Asia biobank have launched (65), both with the aim
of solving the problem of lack of global representation. Similar
initiatives are found in Brazil (66). Due to the heterogeneity
of the samples and different collection strategies of existing
biobanks, adequate skills training, capacity-building of LMIC-
based researchers, and regulatory environments would need to
be in place to support standardization of biobanks globally
(63), as well as the infrastructure (such as 24-h electricity) for
sample storage.
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THE NEED FOR LIFE-COURSE BASED
APPROACHES TO WOMEN’S HEALTH
Health systems in low-resource settings are often designed to
provide emergency services only. Preventative services, however,
are fundamental to ensuring a healthy population. A recent study
showed that each dollar spent on a package of essential preventive
services leads to a net health gain of 1.8 dollars in India (67).
Provision of integrated care for women throughout their life-
course is one way in which women may be engaged within the
health system at key intervals in their life. By using entry points
(e.g., antenatal care) into the health system as opportunities to
engage women, opportunistic screening for cardiometabolic risk
factors might be feasible at critical points during the life-course.
There are few integrated care models that link antenatal
care and non-communicable disease (NCD) prevention (68–71),
although those demonstrating effectiveness for communicable
diseases such as HIV and life-long health, exist (72, 73). Future
research into how existing successful models of integrated care
(such as the HIV programmes in sub-Saharan Africa) could
be adapted for NCD prevention will be valuable in designing
health systems responsive to the needs of women throughout
their life-course.
There is a 2-fold increased risk of developing CVD, and a
3-5-fold risk of chronic hypertension in the decades following
a pregnancy complicated by HDP (59, 74–77). The cumulative
incidence of T2DM following GDM increases markedly within
the first 5 years postpartum and plateaus after 10 years (45,
78). The American Heart Association (79) and the American
Diabetes Association (80) have recommended incorporating
pregnancy-related risk factors as part of screening for adult
cardiovascular disease (81). Postpartum screening for ongoing
problems with BP (79, 82) and glucose control through the
use of an OGTT at 6–12 weeks postpartum and 1–3 yearly
thereafter are advised (80). Despite these recommendations, most
women with a complicated pregnancy do not routinely receive
postpartum follow-up (83, 84) and certainly not for 5 years
following the index pregnancy, when the long-term sequelae are
likely to manifest.
Although challenges to postpartum screening of women
are faced worldwide, there are specific contextual challenges
in LMICs. Postnatal follow-up is lower in LMICs than in
high income settings (85, 86). In low-resource settings, the
burden of CMDs on daily life, household expenditure and
economic stability have considerable implications for women and
their entire household. Cultural practices after birth, workforce
shortages, particularly in rural areas, and a lack of health
system infrastructure are additional barriers to providing life-
long care. Many women with hypertension and T2DM remain
undiagnosed, although population-based screening for GDM
shows high rates of conversion from GDM to T2DM in both
urban and rural areas of LMICs (87). Further education and
training of women and healthcare staff are needed to encourage
postpartum follow-up and repeat testing of women at high risk
of CMDs (84). Postpartum interventions targeting high-risk
women might learn from adult NCD prevention programmes
that have shown evidence of clinical benefit (88, 89). Successful
lifestyle interventions are characterized by addressing more
than one area of prevention and taking a holistic approach to
change (90).
IMPROVING EQUITY AND ACCESS TO
AFFORDABLE TREATMENTS FOR CMDS
A study of 596 urban and rural communities in 18 countries
concluded that improving the availability and affordability of
medicines for CMDs is essential for increasing their uptake and
use (91). This is of great importance for women identified at
high-risk of CMDs early in their life-course. Although common
medications for cardiovascular disease and diabetes are widely
TABLE 1 | Summary of research recommendations.
Recommended area of research Sub-topics Skills required
Community-level interventions for
High-Risk Pregnancies (HRPs)
Development and evaluation of affordable point of care tests
for HRPs.
Community engagement for developing contextually-relevant
and usable tools in low resource settings.
Designing and evaluating community-based interventions
through robust clinical trials and significant clinical endpoints.
Novel methodologies for real-world, pragmatic clinical trials.
Pragmatic evidence-based guidelines for screening and
diagnosis of HRPs in the community.
Contextual-based multidisciplinary research to guide
development.
Building the evidence-base for accurate cardiovascular risk
prediction in high-risk pregnant women.
Building capacity for local LMIC biobanks and data repositories,
alongside improving local research capabilities and governance
systems.
Task-sharing and workforce planning Understanding the needs of healthcare workers in low- resource
settings.
Life-course approaches to
women’s health
Integrated care linking antenatal care to long-term
women’s health.
Learning from other successful models for integrated care
throughout the life-course e.g., HIV.
Improving equity and access Advocacy aimed at Governments to provide essential
medications for secondary prevention of CMDs.
Understanding the socio-cultural barriers to prescribing and
medicine use in low resource settings.
Contextually-based research involving social scientists and
anthropologists.
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available in some LMICs, the out-of-pocket expenditure for
households already struggling to meet their daily needs, is a
significant barrier to their continued life-long use for women
diagnosed with CMDs earlier in their life-course. The situation is
even more pronounced in rural areas (92). Even with improved
access to affordable medicines, there are significant socio-cultural
barriers affecting compliance to lifelong treatment (93).
The WHO has committed to achieving the goal of 80%
availability of affordable, essential medicines for NCDs by 2025
in their Global Action Plan (94). Current rates of medicine
use for the secondary prevention of CVD are, however,
substantially lower (91, 92, 95). The proportion of patients
with coronary heart disease receiving medications for secondary
prevention of CVD in 10 countries (including several LMICs)
in the Prevention of REcurrences of Myocardial Infarction
and StrokE (WHO-PREMISE) PREMISE study, was lower
than 50% for all major classes of CVD prevention medicines,
including beta blockers (48%), ACE inhibitors (40%), and
statins (30%) (96).
Governments need to set policy objectives to ensure that
essential medicines to stem the tide of the rising CMD epidemic
are affordable and available to their populations, including those
in rural areas, by ensuring continuity of supply chains, i.e.,
the manufacturing, transport and distribution of medicines.
Multidisciplinary research is needed to explore socio-cultural
barriers to prescribing and taking medications, if we are to
ensure that women with, or at risk of CMDs in LMICs, receive
essential care.
DISCUSSION: THE RESEARCH AGENDA
FOR LMICS
Only a multi-dimensional research strategy can help improve
women’s health in LMICs. Our review highlights the need for
further well-designed experimental studies of novel technologies
and biomarkers, embedded within the real-world context. Such
studies would need to be adequately powered to demonstrate
tangible benefit to clinical outcomes, such as maternal and
neonatal mortality in the short-term, and cardiovascular
endpoints in the longer term, and include cost-effectiveness
analyses for future scalability. Data collection andmonitoring are
important strategies for improving healthcare provider practices
(90). Future research should prioritize high-quality community-
based data collection and linkage to existing hospital level health
information systems, through prospective cohort studies with
appropriate representation of women living in low-resource
settings. Exploration of the complex social factors that impact
the health of women both during pregnancy and beyond, with
reference to CMDs has also been highlighted as a key area for
future research (see Table 1).
The Academy of Medical Sciences have emphasized the need
to develop locally driven solutions and diagnostics for NCDs,
including disruptive technologies (17). Significant challenges
include the commercially unattractive nature of research into
novel low-cost diagnostics for low-resource settings, affecting
the development and scalability of new diagnostic tests (17).
Nevertheless, given that pregnancy complications associated
with future CMDs still result in significant maternal mortality
worldwide (97), there is a moral imperative to give women in
LMICs the same access as those living in HICs to screening
tests that predict life-threatening conditions in pregnancy,
and beyond.
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